Revolution Medicines, Inc. (NASDAQ:RVMD) to Post Q1 2025 Earnings of ($0.83) Per Share, HC Wainwright Forecasts

Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) - HC Wainwright issued their Q1 2025 earnings estimates for Revolution Medicines in a research report issued on Monday, May 13th. HC Wainwright analyst R. Burns anticipates that the company will post earnings of ($0.83) per share for the quarter. HC Wainwright has a "Buy" rating and a $44.00 price objective on the stock. The consensus estimate for Revolution Medicines' current full-year earnings is ($3.13) per share. HC Wainwright also issued estimates for Revolution Medicines' Q2 2025 earnings at ($0.85) EPS, Q3 2025 earnings at ($0.88) EPS, Q4 2025 earnings at ($0.90) EPS and FY2025 earnings at ($3.46) EPS.

Several other research analysts also recently weighed in on the stock. Raymond James upgraded shares of Revolution Medicines from an "outperform" rating to a "strong-buy" rating and upped their target price for the company from $36.00 to $48.00 in a research note on Wednesday, April 10th. Piper Sandler assumed coverage on shares of Revolution Medicines in a research note on Monday, March 11th. They issued an "overweight" rating and a $43.00 target price for the company. Wedbush upped their target price on shares of Revolution Medicines from $42.00 to $46.00 and gave the company an "outperform" rating in a research note on Thursday, May 9th. Oppenheimer upped their target price on shares of Revolution Medicines from $43.00 to $45.00 and gave the company an "outperform" rating in a research note on Friday, April 12th. Finally, Needham & Company LLC restated a "buy" rating and issued a $46.00 target price on shares of Revolution Medicines in a research note on Thursday, May 9th. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $43.20.

Revolution Medicines Trading Up 0.6 %

RVMD traded up $0.21 during trading on Tuesday, hitting $37.38. 947,179 shares of the company's stock were exchanged, compared to its average volume of 1,344,518. Revolution Medicines has a 1 year low of $15.44 and a 1 year high of $40.21. The stock has a 50 day moving average price of $34.22 and a 200 day moving average price of $28.95. The firm has a market cap of $6.17 billion, a P/E ratio of -9.97 and a beta of 1.46.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.05. During the same quarter in the previous year, the company earned ($0.72) EPS. The firm's revenue was down 100.0% compared to the same quarter last year.

Institutional Trading of Revolution Medicines

Large investors have recently modified their holdings of the company. Wellington Management Group LLP grew its position in Revolution Medicines by 2.7% in the 3rd quarter. Wellington Management Group LLP now owns 10,572,475 shares of the company's stock valued at $292,646,000 after buying an additional 282,786 shares in the last quarter. Vanguard Group Inc. grew its position in Revolution Medicines by 3.2% in the 3rd quarter. Vanguard Group Inc. now owns 9,643,591 shares of the company's stock valued at $266,935,000 after buying an additional 303,088 shares in the last quarter. Walleye Capital LLC bought a new position in Revolution Medicines in the 3rd quarter valued at about $2,644,000. Mirae Asset Global Investments Co. Ltd. grew its position in Revolution Medicines by 45.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 80,405 shares of the company's stock valued at $2,306,000 after buying an additional 25,160 shares in the last quarter. Finally, Victory Capital Management Inc. grew its position in Revolution Medicines by 392.5% in the 3rd quarter. Victory Capital Management Inc. now owns 342,359 shares of the company's stock valued at $9,476,000 after buying an additional 272,848 shares in the last quarter. Institutional investors and hedge funds own 94.34% of the company's stock.

Insiders Place Their Bets

In other Revolution Medicines news, General Counsel Jeff Cislini sold 1,252 shares of the stock in a transaction on Monday, March 18th. The shares were sold at an average price of $31.58, for a total transaction of $39,538.16. Following the sale, the general counsel now directly owns 55,874 shares of the company's stock, valued at $1,764,500.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CFO Jack Anders sold 10,000 shares of the stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $40.03, for a total value of $400,300.00. Following the sale, the chief financial officer now owns 101,959 shares of the company's stock, valued at approximately $4,081,418.77. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, General Counsel Jeff Cislini sold 1,252 shares of the stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $31.58, for a total transaction of $39,538.16. Following the completion of the sale, the general counsel now directly owns 55,874 shares in the company, valued at approximately $1,764,500.92. The disclosure for this sale can be found here. Over the last three months, insiders have sold 28,705 shares of company stock valued at $1,031,049. Company insiders own 8.50% of the company's stock.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.